Abstract
The disappointing results of the large, randomized, controlled trials showing no benefit of vaccines in patients with advanced and metastatic melanoma call for a reassessment of the development of therapeutic vaccines and the importance of better immune monitoring methodology, such as adoptive T-cell therapy with lymphodepletion.
MeSH terms
-
Cancer Vaccines / administration & dosage*
-
Cancer Vaccines / immunology
-
Dose-Response Relationship, Drug
-
Humans
-
Immunotherapy*
-
Interleukin-2 / therapeutic use
-
Melanoma / pathology*
-
Melanoma / secondary
-
Melanoma / therapy*
-
Neoplasm Metastasis
-
Neoplasm Staging
-
Randomized Controlled Trials as Topic
-
Skin Neoplasms / pathology*
-
Skin Neoplasms / therapy*
Substances
-
Cancer Vaccines
-
Interleukin-2